Discontinuation of Disease-Modifying Therapy for Patient with Relapsing-Remitting Multiple Sclerosis

被引：0
|
作者：
Yano, Hajime [1 ,2 ]
Gonzalez, Cindy T. [1 ,2 ]
Healy, Brian C. [1 ,2 ]
Glanz, Bonnie I. [1 ,2 ]
Weiner, Howard L. [1 ,2 ]
Chitnis, Tanuja [3 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurol, Ann Romney Ctr Neurol Dis, Boston, MA 02115 USA
[2] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurol, Partners Multiple Sclerosis Ctr, Boston, MA 02115 USA
[3] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurol, Partners MS Ctr, Boston, MA 02115 USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P061
引用
收藏
页码：47 / 47
页数：1
相关论文
共 50 条
  • [31] The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis
    Bozkaya, Duygu
    Livingston, Terrie
    Migliaccio-Walle, Kristen
    Odom, Tanner
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (03) : 297 - 302
  • [32] The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
    Marco Biolato
    Assunta Bianco
    Matteo Lucchini
    Antonio Gasbarrini
    Massimiliano Mirabella
    Antonio Grieco
    CNS Drugs, 2021, 35 : 861 - 880
  • [33] Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis
    Lucchetta, Rosa C.
    Tonin, Fernanda S.
    Borba, Helena H. L.
    Leonart, Leticia P.
    Ferreira, Vinicius L.
    Bonetti, Aline F.
    Riveros, Bruno S.
    Becker, Jefferson
    Pontarolo, Roberto
    Fernandez-Llimos, Fernando
    Wiens, Astrid
    CNS DRUGS, 2018, 32 (09) : 813 - 826
  • [34] The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
    Biolato, Marco
    Bianco, Assunta
    Lucchini, Matteo
    Gasbarrini, Antonio
    Mirabella, Massimiliano
    Grieco, Antonio
    CNS DRUGS, 2021, 35 (08) : 861 - 880
  • [35] Comorbidity and persistence of disease-modifying therapy use in relapsing remitting multiple sclerosis
    Parks, Natalie E.
    Andreou, Pantelis
    Marrie, Ruth Ann
    Fisk, John
    Bhan, Virender
    Kirkland, Susan A.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 56
  • [36] Treatment satisfaction with injectable disease-modifying therapy in patients with isolated demyelinating syndrome or relapsing-remitting multiple sclerosis
    Fernandez, O.
    Forner, M.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 282 - 282
  • [37] The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosis
    Glasmacher, Stella A.
    Kearns, Patrick K. A.
    Hassan, Zackary
    Connick, Peter
    Tauber, Simone
    Reetz, Kathrin
    Foley, Peter
    Chandran, Siddharthan
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 63
  • [38] Long-term adherence to first disease-modifying drug and reasons for discontinuation in 194 patients with relapsing-remitting multiple sclerosis
    Jacob, A
    Rashid, S
    Ramtahal, J
    Mahavish, K
    Young, C
    Boggild, M
    MULTIPLE SCLEROSIS, 2005, 11 : S157 - S158
  • [39] Analysis of the efficiency of combining disease-modifying treatment and phytotherapy in patients with relapsing-remitting multiple sclerosis
    Barnaulov, O. D.
    Osipova, T. V.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 723 - 723
  • [40] Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran
    Imani, Ali
    Golestani, Mina
    IRANIAN JOURNAL OF NEUROLOGY, 2012, 11 (03) : 87 - 90
12345